Detalhe da pesquisa
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001711
2.
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Mult Scler
; 30(2): 177-183, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38130041
3.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
N Engl J Med
; 383(6): 546-557, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757523
4.
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Mult Scler
; 29(14): 1808-1818, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37978852
5.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 29(14): 1795-1807, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37905526
6.
Fluid phase biomarkers in multiple sclerosis.
Curr Opin Neurol
; 35(3): 286-292, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674070
7.
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Mult Scler
; 28(1): 132-138, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764197
8.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Mult Scler
; 28(12): 1944-1962, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35765217
9.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Mult Scler
; 28(3): 429-440, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240656
10.
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
Mult Scler
; 28(14): 2177-2189, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000489
11.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Mult Scler
; 28(9): 1424-1456, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196927
12.
Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Mult Scler
; 27(11): 1803-1805, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33666121
13.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med
; 376(3): 221-234, 2017 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28002679
14.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
N Engl J Med
; 376(3): 209-220, 2017 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28002688
15.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler
; 26(1): 48-56, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30785358
16.
The Heat Shock Protein HSP70 Promotes Th17 Genes' Expression via Specific Regulation of microRNA.
Int J Mol Sci
; 21(8)2020 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32316658
17.
Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis.
Neurol Neurochir Pol
; 54(5): 410-415, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33085075
18.
Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for the routinely used magnetic resonance imaging protocol in patients with multiple sclerosis.
Pol J Radiol
; 85: e272-e276, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32612727
19.
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Mult Scler
; 25(12): 1605-1617, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30289355
20.
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler
; 25(9): 1255-1262, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043658